Changes

[[File:Atypical ductal hyperplasia with immunotyping.jpg|thumb|300px400px|Histological appearance of atypical ductal hyperplasia (ADH) and immunohistochemical phenotype:<ref>{{cite journal|last1=Rageth|first1=Christoph J.|last2=Rubenov|first2=Ravit|last3=Bronz|first3=Cristian|last4=Dietrich|first4=Daniel|last5=Tausch|first5=Christoph|last6=Rodewald|first6=Ann-Katrin|last7=Varga|first7=Zsuzsanna|title=Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens|journal=Breast Cancer|volume=26|issue=4|year=2018|pages=452–458|issn=1340-6868|doi=10.1007/s12282-018-00943-2}} This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)</ref> <br>- A - One focus (< 2 mm) of two architecturally disarranged cross sections of tubuli showing a monotonous intraductal proliferation with secondary intraluminal architecture.<br>- B - One area of an ADH with associated intraluminal calcifications.<br>- C - Higher magnification of ADH shows low-grade nuclear atypia and monotonous cell proliferation along with secondary intraluminal architecture.<br>- D - Strong and uniform expression of estrogen receptors (ER). ER immunohistochemistry. <br>- E - Lack of basal cytokeratins (CK5/6). CK5/6 immunohistochemistry.]]